Tuesday 5th April 2016
|Text too small?|
Iona Weir, chief executive of Auckland-based Decima Health, will get the chance to pitch the eczema treatment she developed to a global dermatology conference in the US after organisers liked her abstract so much they asked her to be a keynote speaker.
Weir will address the International Conference on Clinical and Experimental Dermatology in Chicago in May about Atopsis, a product that grew out of her Ph.D. in 1997 on programmed cell death in plants known as apoptosis.
Her research showed apoptosis in plants was reversible, unlike in animals, and she was able to extract "critical reactions" in plants that could be put in a cream as a topical application for skin conditions in humans, such as eczema and acne. The extract encourages the body's immune response to attack affected areas and repair damaged cells.
"By manipulating this reversibility in plants I have been able to create Atopsis to manipulate apoptosis and immune function in human cells to stimulate cell repair and growth," Weir said. Clinical trials in the US and New Zealand both showed a reduction in the symptoms of eczema, opening the door for a larger US study, she said.
Weir won an international award for her original Ph.D. and was able to continue her research with a grant from the Marsden Fund. A grant from Callaghan Innovation helped fund the double blind placebo controlled clinical trial completed by Southern Clinical Trials Group at the end of 2015.
Decima has set up a subsidiary, Bionona, to pursue global partnerships for the release of Atopsis. Bionona is chaired by Paul Dallimore, former executive chairman of National Property Trust and chair of Highgate Group.
(BusinessDesk receives funding to help cover the commercialisation of innovation from Callaghan Innovation.)
No comments yet
NZ dollar falls with Aussie after Westpac's RBA rate cut call
Intuit juggernaut grows QuickBooks subscribers but momentum slows
Reaction to Budget rules relaxation shows balance 'about right', says Ardern
Augusta lifts net profit six fold as investors flock into new funds
Annual exports to China top $15 billion for first time
Gentrack posts $8.7M loss on CA Plus write-down
Westpac says RBNZ capital proposals would add $6,000 p.a. to an Auckland mortgage
Cavalier says market conditions still challenging
Ryman hikes dividend as annual earnings grow on wider development margin
24th May 2019 Morning Report